Ricerca Biosciences/Instem Collaboration Delivers Improved Quality in Drug Safety Studies
Ricerca Biosciences
is pleased to announce the successful result of a partnership with
Instem
, a leading provider of laboratory data and information management solutions. The collaboration resulted in the development of a novel approach to eliminating potential misdosing during drug safety studies.
With the goal of improving quality management processes for clients and ensuring the integrity of study data, the Ricerca team in Lyon, France, approached Instem and proposed an upgrade to their
Provantis
software suite, which would help eliminate dosage errors. The Ricerca team created the requirement specifications and Instem enhanced the latest version of Provantis, enabling it to automatically verify and control correct dosing before administration by using existing bar code technology. The enhanced functionality replaces manual controls, which are not completely reliable, and streamlines the drug dosing process, thereby eliminating the potential for errors.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
